Company profile
Dynavax Technologies company profile
Dynavax is a commercial stage biopharmaceutical company developing and commercializing novel vaccines. The Company's first commercial product, HEPLISAV-B® [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the U.S. and the European Union for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older. Dynavax is also advancing CpG 1018TM adjuvant as a premier vaccine adjuvant through research collaborations and partnerships. Current collaborations are focused on adjuvanted vaccines for COVID-19, pertussis and universal influenza.
Business identity
- Website
- http://www.dynavax.com
- Contact email
- [email protected]
- Phone number
- +1 510 848 1327
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 00251-00500 employees
- Revenue range
- $100K+
- Founded
- 1996-01-01
Headquarters
- Headquarters
- Berkeley, California, United States
- Postal code
- 94710
- Country code
- US
- Continent
- North America